Over the past 12 months, 9 insiders at Mineralys Therapeutics, Inc. filed 74 open-market SEC Form 4 transactions on MLYS: 4 purchases worth $53.8M and 70 sales worth $79.3M. Insiders have been net sellers over this period. The most recent filing was on Jul 15, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 15, 26 | David Malcom RodmanChief Medical Officer | SELL | 6.3K | $26.61 | $169K |
| Jul 13, 26 | Jon CongletonChief Executive Officer, Director | SELL | 10.7K | $27.24 | $291K |
| Jul 13, 26 | David Malcom RodmanChief Medical Officer | SELL | 14.1K | $27.58 | $388K |
| Jul 9, 26 | David Malcom RodmanChief Medical Officer | SELL | 2.2K | $30.30 | $66K |
| Jun 30, 26 | Jon CongletonChief Executive Officer | SELL | 58.0K | $26.82 | $1.5M |
| Jun 17, 26 | Daphne Karydas | SELL | 3.0K | $25.00 | $75K |
| Jun 17, 26 | David Malcom RodmanChief Medical Officer | SELL | 4.6K | $25.00 | $115K |
| Jun 15, 26 | David Malcom RodmanChief Medical Officer | SELL | 9.9K | $23.81 | $235K |
| Jun 12, 26 | David Malcom RodmanChief Medical Officer | SELL | 6.3K | $23.93 | $152K |
| Jun 10, 26 | David Malcom RodmanChief Medical Officer | SELL | 2.2K | $25.00 | $54K |
| Apr 13, 26 | Jon CongletonChief Executive Officer | SELL | 15.7K | $26.83 | $422K |
| Mar 30, 26 | Rajeev M. ShahDirector | BUY | 58.3K | $24.16 | $1.4M |
| Mar 27, 26 | Rajeev M. ShahDirector | BUY | 310.7K | $23.67 | $7.4M |
| Mar 17, 26 | David Malcom RodmanChief Medical Officer | SELL | 417 | $25.65 | $11K |
| Mar 13, 26 | David Malcom RodmanChief Medical Officer | SELL | 10.7K | $27.82 | $278K |
| Mar 12, 26 | David Malcom RodmanChief Medical Officer | SELL | 6.3K | $27.37 | $174K |
| Mar 9, 26 | David Malcom RodmanChief Medical Officer | SELL | 2.2K | $26.84 | $58K |
| Feb 17, 26 | David Malcom RodmanChief Medical Officer | SELL | 417 | $27.59 | $12K |
| Feb 13, 26 | David Malcom RodmanChief Medical Officer | SELL | 6.3K | $27.58 | $175K |
| Feb 12, 26 | David Malcom RodmanChief Medical Officer | SELL | 5.8K | $29.64 | $169K |
| Feb 9, 26 | David Malcom RodmanChief Medical Officer | SELL | 2.2K | $30.21 | $66K |
| Jan 20, 26 | David Malcom RodmanChief Medical Officer | SELL | 416 | $32.10 | $13K |
| Jan 14, 26 | David Malcom RodmanChief Medical Officer | SELL | 11.4K | $32.61 | $371K |
| Jan 13, 26 | David Malcom RodmanChief Medical Officer | SELL | 7.7K | $32.75 | $252K |
| Jan 12, 26 | Jon CongletonChief Executive Officer | SELL | 9.1K | $33.15 | $294K |
| Jan 12, 26 | Adam Scott LevyCFO and Secretary | SELL | 10.8K | $32.14 | $346K |
| Jan 12, 26 | David Malcom RodmanChief Medical Officer | SELL | 6.3K | $32.32 | $205K |
| Jan 9, 26 | David Malcom RodmanChief Medical Officer | SELL | 2.2K | $33.27 | $72K |
| Jan 5, 26 | David Malcom RodmanChief Medical Officer | SELL | 139.2K | $35.53 | $4.8M |
| Jan 2, 26 | David Malcom RodmanChief Medical Officer | SELL | 70.0K | $35.87 | $2.5M |
| Nov 20, 25 | Catalys Pacific Fund, LpTenPercentOwner | SELL | 1.00M | $43.35 | $43.4M |
| Nov 13, 25 | Daphne KarydasDirector | SELL | 10.1K | $46.36 | $463K |
| Nov 13, 25 | Alexander M GoldDirector | SELL | 12.7K | $46.50 | $593K |
| Nov 12, 25 | Alexander M GoldDirector | SELL | 5.0K | $47.28 | $233K |
| Nov 11, 25 | Jon CongletonChief Executive Officer | SELL | 112.3K | $46.89 | $5.1M |
| Nov 11, 25 | Alexander M GoldDirector | SELL | 10.0K | $47.08 | $424K |
| Nov 11, 25 | Adam Scott LevyCFO and Secretary | SELL | 38.9K | $46.88 | $1.8M |
| Oct 15, 25 | David Malcom RodmanChief Medical Officer | SELL | 10.4K | $43.01 | $446K |
| Oct 13, 25 | Jon CongletonChief Executive Officer | SELL | 13.5K | $43.03 | $578K |
| Oct 13, 25 | Adam Scott LevyCFO and Secretary | SELL | 7.4K | $42.26 | $309K |
| Sep 15, 25 | David Malcom RodmanChief Medical Officer | SELL | 9.3K | $36.47 | $334K |
| Sep 4, 25 | Srinivas AkkarajuDirector | BUY | 588.2K | $25.50 | $15.0M |
| Sep 4, 25 | Ra Capital Management, L.p.Director | BUY | 1.18M | $25.50 | $30.0M |
| Aug 13, 25 | David Malcom RodmanChief Medical Officer | SELL | 11.4K | $12.93 | $147K |
| Jul 30, 25 | Adam Scott LevyCFO and Secretary | SELL | 51.5K | $15.10 | $757K |
| Jul 29, 25 | Adam Scott LevyCFO and Secretary | SELL | 807 | $14.00 | $11K |
| Jul 28, 25 | Adam Scott LevyCFO and Secretary | SELL | 12.9K | $14.04 | $182K |
| Jul 14, 25 | David Malcom RodmanChief Medical Officer | SELL | 11.4K | $14.59 | $166K |
| Jul 11, 25 | Jon CongletonChief Executive Officer | SELL | 15.9K | $14.51 | $230K |
| Jul 11, 25 | Adam Scott LevyCFO and Secretary | SELL | 10.8K | $14.45 | $155K |
Over the past 12 months, insiders at Mineralys Therapeutics, Inc. filed 4 open-market purchases worth $53.8M and 70 sales worth $79.3M on MLYS, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 15, 26.
The largest recent open-market MLYS insider purchase in our data was $30.0M by Ra Capital Management, L.p., Director, filed on Sep 4, 25.
9 different insiders at Mineralys Therapeutics, Inc. filed open-market SEC Form 4 transactions on MLYS over the last 12 months.
InsiderTape plots every MLYS insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Mineralys Therapeutics, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →